Clinical trials: Placebo Group
Healthy
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
Main study: To investigate safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of BEA 2180 BR Sub-study; To investigate whether treatment with 36 μg tiotropium bromide is able to protect of methacholine-induced…
- Trial name
- NCT02263976
- Testing
- BEA 2180 BR, Respimat® A 4, Methacholine Chloride
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis
This clinical trial aims to explore whether the drug ZL-82 tablets can be used to treat moderate to severe atopic dermatitis in adults, and to understand the safety and tolerability of the drug.
- Trial name
- NCT07193589
- Testing
- The high-dose group of ZL-82 tablets, The low-dose group of ZL-82 tablets
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Onychomycosis
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.
Onychomycosis is a common condition accounting for approximately half of all nail disorders. It is most commonly caused by dermatophytes.
- Trial name
- NCT00356915
- Testing
- Itraconazole 100mg capsules, Itraconazole 200mg tablets
- Where
- 68 sites in United States, Canada and 5 more
- Volunteers
- 1,381 people
- Sponsor
- Stiefel, a GSK Company
Dental Pain
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain either perioperatively or postoperatively in a third molar extraction pain model, and to further evaluate the drug's…
- Trial name
- NCT00542035
- Testing
- ARRY-371797, p38 inhibitor; oral
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pfizer
Overactive Bladder
A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
This study is designed to confirm if 8mg of fesoterodine is more effective in reducing overactive bladder symptoms than 4mg of fesoterodine.
- Trial name
- NCT01302067
- Testing
- Fesoterodine 8mg, Fesoterodine 4mg
- Where
- 293 sites in United States, Argentina and 25 more
- Volunteers
- 2,012 people
- Sponsor
- Pfizer
Urinary Incontinence, Overactive Bladder
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.
- Trial name
- NCT00290563
- Testing
- MK0594
- Volunteers
- 557 people
- Sponsor
- Vyne Therapeutics Inc.
Tinea Cruris, Jock Itch
Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo (no active treatment), when used in subjects with tinea cruris, also known as jock itch.
- Trial name
- NCT00750152
- Testing
- NAFT-500
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Iron Deficiency Anemia, B12 Deficiency Anemia
Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?
A parallel group, quadruple blind, placebo-controlled, randomized control trial with 2x2 factorial design to determine the effect of simultaneous IV ferric carboxymaltose and IM hydroxycobalamin supplementation in anemic Indian…
- Trial name
- ALOHA (NCT04627181)
- Testing
- Ferric carboxymaltose, Hydroxycobalamin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Christian Medical College, Vellore, India
Healthy Volunteers, Safety
Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects
The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.
- Conditions
- Healthy Volunteers, Safety, Tolerability
- Trial name
- NCT01166698
- Testing
- AZD9819
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Developmental and Epileptic Encephalopathy, Dravet Syndrome
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
- Conditions
- Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome
- Trial name
- PACIFIC (NCT05364021)
- Testing
- LP352
- Where
- 34 sites in United States, Australia
- Volunteers
- 52 people
- Sponsor
- Longboard Pharmaceuticals
Sickle Cell Disease, Sickle Cell Anemia
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks…
- Trial name
- NCT00040677
- Testing
- Low Dose ICA-17043, High dose ICA-17043
- Where
- 19 sites in United States
- Volunteers
- 90 people
- Sponsor
- Icagen
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
- Trial name
- NCT04510298
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Ischemic Stroke
Effect of F2695 on Functional Recovery After Ischemic Stroke
The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.
- Trial name
- LIFE (NCT01639014)
- Testing
- F2695
- Where
- 87 sites in Belgium, Czechia and 9 more
- Volunteers
- 532 people
- Sponsor
- Pierre Fabre Medicament
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07108699
- Testing
- HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- STRIVE (NCT00909532)
- Testing
- Ivacaftor
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Anaemia
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease.
- Trial name
- NCT02689206
- Testing
- GSK1278863
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- GlaxoSmithKline
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1).
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
- Trial name
- NCT00288704
- Testing
- rilonacept 160 mg
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.